Addiction Medications

Medications used to manage addiction can be highly complex and are often part of a long-term treatment regimen. That’s why Avella is dedicated to giving you and your patients guidance, support and education. 

Avella provides several addiction medications--including newly released drugs and those that may be hard to find--available at our pharmacy locations and through our delivery and mail order services.

We are also proud to be the exclusive specialty pharmacy provider of the Probuphine (buprenorphine) implant for opioid addiction. Please see full Prescribing Information, including BOXED Warning, for Important Safety Information. Learn more at:

Learn more about these specialty medications related to addiction management.


BELBUCA® (buprenorphine) contains an opioid (narcotic) medication that is used to help manage pain severe enough to require daily, around-the-clock treatment with an opioid. 


Probuphine (buprenorphine) implant for subdermal administration (CIII) is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product.


Sublocade is the first once-monthly injectable buprenorphine formulation for the treatment of moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a transmucosal buprenorphine-containing product followed by dose adjustment for a minimum of seven days.
Visit for full prescribing information.


Suboxone (buprenorphine and naloxone) Sublingual Film (CIII) is a prescription medicine indicated for treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. 


Vivitrol (naltrexone for extended-release injectable suspension) is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with Vivitrol. 


Zubsolv (buprenorphine and naloxone) sublingual tablets for sublingual administration (CIII) is a partial opioid agonist indicated for treatment of opioid dependence. Prescription use of this project is limited under the Drug Addiction Treatment Act.